J&J Wins FDA Approval for Diabetes Combo Drug

J&J’s Janssen Pharmaceuticals unit was granted FDA approval for Invokamet, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.

According to J&J, Invokamet combines the SGLT2 blocker canagliflozin (approved in March 2013) with the commonly prescribed treatment metformin, creating a single tablet that lowered blood sugar, lowered blood pressure and reduced body weight in Phase III trials.

Invokamet is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States.

Read the press release

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments